Payment overview · 2025
General Payments
$744.24
38 reported records · 19 companies
Healthcare provider profile · identity verified
Matthew Chung, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CUYAHOGA FALLS, OH · NPI 1861452948
Verified facts
What the public records show
CMS Open Payments records show Matthew Chung, MD received $744.24 in general payments during 2025 across 38 reported records.
ABBVIE INC. accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $139.69 | 18.8% | 10 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $89.21 | 12.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $71.63 | 9.6% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $60.02 | 8.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.62 | 6.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.44 | 5.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.30 | 5.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $33.59 | 4.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $31.83 | 4.3% | 2 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $27.30 | 3.7% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $27.18 | 3.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $21.56 | 2.9% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.38 | 2.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.36 | 2.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.77 | 2.7% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.35 | 2.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.97 | 2.1% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $15.54 | 2.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.50 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $744.24 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $117.79 | 9 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $89.21 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $60.02 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $50.89 | 3 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Optinose US, Inc., Paratek Pharmaceuticals, Inc. | $47.68 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $37.44 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $37.30 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $33.59 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $31.83 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.03 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $21.56 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 63 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
48 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
230 | 46 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
230 | 46 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
48 | 48 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1047 | 252 |
| Amlodipine Besylate | Amlodipine Besylate | 735 | 176 |
| Levothyroxine Sodium | Levothyroxine Sodium | 519 | 115 |
| Omeprazole | Omeprazole | 485 | 107 |
| Lisinopril | Lisinopril | 448 | 115 |
| Losartan Potassium | Losartan Potassium | 370 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 360 | 94 |
| Metoprolol Succinate | Metoprolol Succinate | 299 | 70 |
| Furosemide | Furosemide | 273 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 269 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 260 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 241 | 69 |
| Eliquis | Apixaban | 230 | 46 |
| Gabapentin | Gabapentin | 204 | 54 |
| Trazodone Hcl | Trazodone Hcl | 204 | 52 |
| Metformin Hcl Er | Metformin Hcl | 195 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 194 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 185 | 40 |
| Metformin Hcl | Metformin Hcl | 175 | 49 |
| Potassium Chloride | Potassium Chloride | 160 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 156 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 155 | 45 |
| Simvastatin | Simvastatin | 149 | 35 |
| Carvedilol | Carvedilol | 148 | 42 |
| Tizanidine Hcl | Tizanidine Hcl | 145 | 59 |
| Sertraline Hcl | Sertraline Hcl | 140 | 31 |
| Allopurinol | Allopurinol | 134 | 30 |
| Mirtazapine | Mirtazapine | 128 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 123 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 119 | 29 |
| Montelukast Sodium | Montelukast Sodium | 117 | 27 |
| Buspirone Hcl | Buspirone Hcl | 116 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 111 | 21 |
| Atenolol | Atenolol | 106 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 31 |
| Alendronate Sodium | Alendronate Sodium | 101 | 20 |
| Methylprednisolone | Methylprednisolone | 101 | 90 |
| Azithromycin | Azithromycin | 100 | 84 |
| Quetiapine Fumarate | Quetiapine Fumarate | 92 | 18 |
| Mupirocin | Mupirocin | 88 | 48 |
| Doxycycline Hyclate | Doxycycline Hyclate | 79 | 42 |
| Bupropion Xl | Bupropion Hcl | 77 | 23 |
| Famotidine | Famotidine | 77 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 22 |
| Glimepiride | Glimepiride | 73 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 70 | 12 |
| Spironolactone | Spironolactone | 68 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 67 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 66 | 16 |
| Terazosin Hcl | Terazosin Hcl | 66 | 15 |
| Ezetimibe | Ezetimibe | 65 | 15 |
| Meloxicam | Meloxicam | 64 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 63 | 19 |
| Ozempic | Semaglutide | 63 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 13 |
| Sucralfate | Sucralfate | 56 | 15 |
| Verapamil Er | Verapamil Hcl | 55 | 13 |
| Pregabalin | Pregabalin | 54 | 18 |
| Donepezil Hcl | Donepezil Hcl | 50 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 48 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 48 | 48 |
| Synthroid | Levothyroxine Sodium | 48 | 17 |
| Labetalol Hcl | Labetalol Hcl | 47 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 12 |
| Gemfibrozil | Gemfibrozil | 44 | suppressed |
| Glipizide | Glipizide | 44 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 44 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | 12 |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 36 |
| Farxiga | Dapagliflozin Propanediol | 39 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 17 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 37 | 11 |
| Torsemide | Torsemide | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 11 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Prednisone | Prednisone | 35 | 15 |
| Meclizine Hcl | Meclizine Hcl | 34 | suppressed |
| Nystatin | Nystatin | 34 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 16 |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | 16 |
| Cefdinir | Cefdinir | 32 | 27 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | 12 |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Cilostazol | Cilostazol | 26 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Valsartan | Valsartan | 24 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | suppressed |
| Nystop | Nystatin | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 15 |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Fluocinonide | Fluocinonide | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | 14 |
| Tramadol Hcl | Tramadol Hcl | 17 | 15 |
| Amoxicillin | Amoxicillin | 16 | 15 |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $744.24 · 38 records | ABBVIE INC. | AIRSUPRA, AVVIGO Guidance System, BREZTRI, CAMZYOS, Cologuard Collection Kit, FREESTYLE LIBRE 3, GVOKE HYPOPEN, Heplisav-B, INSPIRE, Korlym, NURTEC ODT, NUZYRA, Ozempic, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, Wegovy, XHANCE, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error